Breaking News, Collaborations & Alliances

Inovio Receives Milestone from MedImmune

After a satisfactory completion of a phase 1 safety review

Inovio Pharmaceuticals has received a milestone payment from MedImmune after MEDI0457 in combination with durvalumab (MEDI4736) successfully completed the phase 1 safety review portion of the study and has advanced to the phase 2 efficacy stage of the trial.    As part of a $700 million 2015 license and collaboration agreement, MedImmune, the global biologics research and development arm of AstraZeneca, is evaluating MEDI0457 in combination with durvalumab, its PD-L1 checkpoint inhibitor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters